|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: IL1A |
Gene summary for IL1A |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | IL1A | Gene ID | 3552 |
| Gene name | interleukin 1 alpha | |
| Gene Alias | IL-1 alpha | |
| Cytomap | 2q14.1 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | P01583 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 3552 | IL1A | P5T-E | Human | Esophagus | ESCC | 8.48e-04 | 2.39e-01 | 0.1327 |
| 3552 | IL1A | P11T-E | Human | Esophagus | ESCC | 4.13e-14 | 1.49e+00 | 0.1426 |
| 3552 | IL1A | P21T-E | Human | Esophagus | ESCC | 8.76e-25 | 1.39e+00 | 0.1617 |
| 3552 | IL1A | P32T-E | Human | Esophagus | ESCC | 3.44e-03 | 3.70e-01 | 0.1666 |
| 3552 | IL1A | P37T-E | Human | Esophagus | ESCC | 4.06e-12 | 6.08e-01 | 0.1371 |
| 3552 | IL1A | P38T-E | Human | Esophagus | ESCC | 6.13e-18 | 1.93e+00 | 0.127 |
| 3552 | IL1A | P47T-E | Human | Esophagus | ESCC | 1.55e-03 | 1.83e-01 | 0.1067 |
| 3552 | IL1A | P49T-E | Human | Esophagus | ESCC | 4.56e-02 | 5.41e-01 | 0.1768 |
| 3552 | IL1A | P52T-E | Human | Esophagus | ESCC | 4.53e-17 | 8.23e-01 | 0.1555 |
| 3552 | IL1A | P83T-E | Human | Esophagus | ESCC | 1.05e-21 | 1.59e+00 | 0.1738 |
| 3552 | IL1A | P89T-E | Human | Esophagus | ESCC | 8.57e-15 | 1.79e+00 | 0.1752 |
| 3552 | IL1A | P107T-E | Human | Esophagus | ESCC | 2.02e-03 | 3.01e-01 | 0.171 |
| 3552 | IL1A | P126T-E | Human | Esophagus | ESCC | 5.59e-03 | 5.29e-01 | 0.1125 |
| 3552 | IL1A | P130T-E | Human | Esophagus | ESCC | 7.86e-32 | 1.40e+00 | 0.1676 |
| 3552 | IL1A | C04 | Human | Oral cavity | OSCC | 1.61e-22 | 1.59e+00 | 0.2633 |
| 3552 | IL1A | C21 | Human | Oral cavity | OSCC | 8.04e-35 | 2.02e+00 | 0.2678 |
| 3552 | IL1A | C43 | Human | Oral cavity | OSCC | 5.78e-05 | 4.08e-01 | 0.1704 |
| 3552 | IL1A | C57 | Human | Oral cavity | OSCC | 2.48e-10 | 7.67e-01 | 0.1679 |
| 3552 | IL1A | C06 | Human | Oral cavity | OSCC | 5.61e-04 | 1.31e+00 | 0.2699 |
| 3552 | IL1A | SYSMH2 | Human | Oral cavity | OSCC | 1.17e-03 | 5.55e-01 | 0.2326 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00513025 | Esophagus | ESCC | regulation of cell division | 97/8552 | 177/18723 | 8.93e-03 | 3.12e-02 | 97 |
| GO:005070810 | Esophagus | ESCC | regulation of protein secretion | 142/8552 | 268/18723 | 9.31e-03 | 3.24e-02 | 142 |
| GO:007121617 | Esophagus | ESCC | cellular response to biotic stimulus | 131/8552 | 246/18723 | 9.85e-03 | 3.39e-02 | 131 |
| GO:000715918 | Esophagus | ESCC | leukocyte cell-cell adhesion | 192/8552 | 371/18723 | 1.03e-02 | 3.51e-02 | 192 |
| GO:004668817 | Esophagus | ESCC | response to copper ion | 27/8552 | 42/18723 | 1.16e-02 | 3.90e-02 | 27 |
| GO:005071416 | Esophagus | ESCC | positive regulation of protein secretion | 76/8552 | 137/18723 | 1.32e-02 | 4.31e-02 | 76 |
| GO:190303717 | Esophagus | ESCC | regulation of leukocyte cell-cell adhesion | 174/8552 | 336/18723 | 1.36e-02 | 4.43e-02 | 174 |
| GO:00300984 | Esophagus | ESCC | lymphocyte differentiation | 192/8552 | 374/18723 | 1.52e-02 | 4.93e-02 | 192 |
| GO:200123320 | Oral cavity | OSCC | regulation of apoptotic signaling pathway | 242/7305 | 356/18723 | 6.66e-29 | 3.24e-26 | 242 |
| GO:01400145 | Oral cavity | OSCC | mitotic nuclear division | 191/7305 | 287/18723 | 1.99e-21 | 3.70e-19 | 191 |
| GO:00073469 | Oral cavity | OSCC | regulation of mitotic cell cycle | 266/7305 | 457/18723 | 3.87e-17 | 3.41e-15 | 266 |
| GO:200123420 | Oral cavity | OSCC | negative regulation of apoptotic signaling pathway | 148/7305 | 224/18723 | 1.71e-16 | 1.36e-14 | 148 |
| GO:190495119 | Oral cavity | OSCC | positive regulation of establishment of protein localization | 196/7305 | 319/18723 | 2.89e-16 | 2.20e-14 | 196 |
| GO:005122219 | Oral cavity | OSCC | positive regulation of protein transport | 187/7305 | 303/18723 | 7.37e-16 | 5.49e-14 | 187 |
| GO:009719120 | Oral cavity | OSCC | extrinsic apoptotic signaling pathway | 142/7305 | 219/18723 | 7.34e-15 | 4.55e-13 | 142 |
| GO:004206020 | Oral cavity | OSCC | wound healing | 237/7305 | 422/18723 | 4.51e-13 | 2.18e-11 | 237 |
| GO:00482852 | Oral cavity | OSCC | organelle fission | 265/7305 | 488/18723 | 3.22e-12 | 1.27e-10 | 265 |
| GO:200123620 | Oral cavity | OSCC | regulation of extrinsic apoptotic signaling pathway | 100/7305 | 151/18723 | 1.07e-11 | 3.90e-10 | 100 |
| GO:00002801 | Oral cavity | OSCC | nuclear division | 237/7305 | 439/18723 | 9.62e-11 | 2.90e-09 | 237 |
| GO:00457879 | Oral cavity | OSCC | positive regulation of cell cycle | 173/7305 | 313/18723 | 3.28e-09 | 7.44e-08 | 173 |
| Page: 1 2 3 4 5 6 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa05022210 | Esophagus | ESCC | Pathways of neurodegeneration - multiple diseases | 318/4205 | 476/8465 | 6.10e-15 | 2.04e-13 | 1.05e-13 | 318 |
| hsa05010210 | Esophagus | ESCC | Alzheimer disease | 263/4205 | 384/8465 | 1.80e-14 | 5.47e-13 | 2.80e-13 | 263 |
| hsa04932210 | Esophagus | ESCC | Non-alcoholic fatty liver disease | 122/4205 | 155/8465 | 5.69e-14 | 1.59e-12 | 8.14e-13 | 122 |
| hsa05020210 | Esophagus | ESCC | Prion disease | 193/4205 | 273/8465 | 6.42e-13 | 1.34e-11 | 6.89e-12 | 193 |
| hsa05418211 | Esophagus | ESCC | Fluid shear stress and atherosclerosis | 109/4205 | 139/8465 | 2.00e-12 | 3.72e-11 | 1.90e-11 | 109 |
| hsa0421829 | Esophagus | ESCC | Cellular senescence | 119/4205 | 156/8465 | 5.89e-12 | 9.40e-11 | 4.81e-11 | 119 |
| hsa0516425 | Esophagus | ESCC | Influenza A | 122/4205 | 171/8465 | 5.01e-09 | 4.79e-08 | 2.45e-08 | 122 |
| hsa0493310 | Esophagus | ESCC | AGE-RAGE signaling pathway in diabetic complications | 72/4205 | 100/8465 | 4.15e-06 | 2.28e-05 | 1.17e-05 | 72 |
| hsa051629 | Esophagus | ESCC | Measles | 90/4205 | 139/8465 | 2.16e-04 | 7.87e-04 | 4.03e-04 | 90 |
| hsa051527 | Esophagus | ESCC | Tuberculosis | 111/4205 | 180/8465 | 7.14e-04 | 2.32e-03 | 1.19e-03 | 111 |
| hsa0532320 | Esophagus | ESCC | Rheumatoid arthritis | 59/4205 | 93/8465 | 4.98e-03 | 1.27e-02 | 6.52e-03 | 59 |
| hsa051339 | Esophagus | ESCC | Pertussis | 48/4205 | 76/8465 | 1.21e-02 | 2.77e-02 | 1.42e-02 | 48 |
| hsa0502238 | Esophagus | ESCC | Pathways of neurodegeneration - multiple diseases | 318/4205 | 476/8465 | 6.10e-15 | 2.04e-13 | 1.05e-13 | 318 |
| hsa0501038 | Esophagus | ESCC | Alzheimer disease | 263/4205 | 384/8465 | 1.80e-14 | 5.47e-13 | 2.80e-13 | 263 |
| hsa0493238 | Esophagus | ESCC | Non-alcoholic fatty liver disease | 122/4205 | 155/8465 | 5.69e-14 | 1.59e-12 | 8.14e-13 | 122 |
| hsa0502038 | Esophagus | ESCC | Prion disease | 193/4205 | 273/8465 | 6.42e-13 | 1.34e-11 | 6.89e-12 | 193 |
| hsa05418310 | Esophagus | ESCC | Fluid shear stress and atherosclerosis | 109/4205 | 139/8465 | 2.00e-12 | 3.72e-11 | 1.90e-11 | 109 |
| hsa0421838 | Esophagus | ESCC | Cellular senescence | 119/4205 | 156/8465 | 5.89e-12 | 9.40e-11 | 4.81e-11 | 119 |
| hsa0516435 | Esophagus | ESCC | Influenza A | 122/4205 | 171/8465 | 5.01e-09 | 4.79e-08 | 2.45e-08 | 122 |
| hsa0493317 | Esophagus | ESCC | AGE-RAGE signaling pathway in diabetic complications | 72/4205 | 100/8465 | 4.15e-06 | 2.28e-05 | 1.17e-05 | 72 |
| Page: 1 2 3 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| IL1A | IL1R1_IL1RAP | IL1A_IL1R1_IL1RAP | IL1 | Cervix | CC |
| IL1A | IL1R2 | IL1A_IL1R2 | IL1 | Endometrium | AEH |
| IL1A | IL1R2 | IL1A_IL1R2 | IL1 | Endometrium | EEC |
| IL1A | IL1R2 | IL1A_IL1R2 | IL1 | HNSCC | ADJ |
| IL1A | IL1R2 | IL1A_IL1R2 | IL1 | HNSCC | OSCC |
| IL1A | IL1R1_IL1RAP | IL1A_IL1R1_IL1RAP | IL1 | HNSCC | Precancer |
| IL1A | IL1R2 | IL1A_IL1R2 | IL1 | HNSCC | Precancer |
| IL1A | IL1R2 | IL1A_IL1R2 | IL1 | Lung | AAH |
| IL1A | IL1R1_IL1RAP | IL1A_IL1R1_IL1RAP | IL1 | Lung | IAC |
| IL1A | IL1R2 | IL1A_IL1R2 | IL1 | Lung | IAC |
| IL1A | IL1R1_IL1RAP | IL1A_IL1R1_IL1RAP | IL1 | Lung | MIAC |
| IL1A | IL1R2 | IL1A_IL1R2 | IL1 | Lung | MIAC |
| IL1A | IL1R2 | IL1A_IL1R2 | IL1 | THCA | ADJ |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| IL1A | SNV | Missense_Mutation | c.125C>A | p.Pro42Gln | p.P42Q | P01583 | protein_coding | tolerated(0.06) | benign(0.167) | TCGA-A2-A3XZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR | |
| IL1A | deletion | Frame_Shift_Del | novel | c.263delT | p.Leu88Ter | p.L88* | P01583 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| IL1A | SNV | Missense_Mutation | c.217N>A | p.Val73Ile | p.V73I | P01583 | protein_coding | tolerated(0.11) | benign(0.012) | TCGA-C5-A1M5-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD | |
| IL1A | SNV | Missense_Mutation | c.518N>T | p.Ser173Leu | p.S173L | P01583 | protein_coding | deleterious(0.04) | benign(0.356) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| IL1A | SNV | Missense_Mutation | novel | c.505G>T | p.Gly169Cys | p.G169C | P01583 | protein_coding | deleterious(0.05) | probably_damaging(0.958) | TCGA-AA-3845-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| IL1A | SNV | Missense_Mutation | novel | c.164N>T | p.Ser55Ile | p.S55I | P01583 | protein_coding | deleterious(0.03) | possibly_damaging(0.876) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| IL1A | SNV | Missense_Mutation | novel | c.466G>A | p.Ala156Thr | p.A156T | P01583 | protein_coding | tolerated(0.26) | benign(0.013) | TCGA-D1-A17Q-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| IL1A | SNV | Missense_Mutation | novel | c.557N>A | p.Ile186Asn | p.I186N | P01583 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-DI-A1BU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
| IL1A | SNV | Missense_Mutation | novel | c.416N>T | p.Ala139Val | p.A139V | P01583 | protein_coding | tolerated(0.23) | benign(0.001) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| IL1A | SNV | Missense_Mutation | novel | c.392A>C | p.Lys131Thr | p.K131T | P01583 | protein_coding | tolerated(0.15) | benign(0.277) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 3552 | IL1A | CELL SURFACE, DRUGGABLE GENOME | RILONACEPT | RILONACEPT | ||
| 3552 | IL1A | CELL SURFACE, DRUGGABLE GENOME | Xilonix | BERMEKIMAB | ||
| 3552 | IL1A | CELL SURFACE, DRUGGABLE GENOME | ABT-981 | |||
| 3552 | IL1A | CELL SURFACE, DRUGGABLE GENOME | RILONACEPT | RILONACEPT | ||
| 3552 | IL1A | CELL SURFACE, DRUGGABLE GENOME | HYDROXYCHLOROQUINE | HYDROXYCHLOROQUINE | 8336306 | |
| 3552 | IL1A | CELL SURFACE, DRUGGABLE GENOME | olanzapine | OLANZAPINE | 21107309 | |
| 3552 | IL1A | CELL SURFACE, DRUGGABLE GENOME | AMG-108 | AMG-108 | ||
| 3552 | IL1A | CELL SURFACE, DRUGGABLE GENOME | IMMUNOSUPPRESSANT | 1703047 | ||
| 3552 | IL1A | CELL SURFACE, DRUGGABLE GENOME | inhibitor | CHEMBL2109653 | BERMEKIMAB | |
| 3552 | IL1A | CELL SURFACE, DRUGGABLE GENOME | MITOMYCIN-C | 8195120 |
| Page: 1 2 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |